COVID-19’s impact on bioanalytical labs

One year later, the impact of the COVID-19 pandemic on business practices, supply chains, timelines and analytical needs for COVID-19 clinical trials have been felt across the bioanalytical community, as therapeutics may now require SARS-CoV-2 antigen and serological testing.

Detalles Bibliográficos
Autores principales: Lavelle, Amy, Micheli, Janine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Newlands Press Ltd 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438945/
https://www.ncbi.nlm.nih.gov/pubmed/34374298
http://dx.doi.org/10.4155/bio-2021-0103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438945/
https://www.ncbi.nlm.nih.gov/pubmed/34374298
http://dx.doi.org/10.4155/bio-2021-0103

Ejemplares similares